In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
To read the full story
Related Article
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
BUSINESS
- Meiji Looks at Sales of 274 Billion Yen from Pharma Biz in FY2026
July 12, 2024
- Leqembi Approved in Hong Kong, Israel: Eisai
July 12, 2024
- Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
- FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
- Taiho Bags Japan, Asian Rights to Arcus’ CD73 Inhibitor
July 10, 2024
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…